DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.06 Bil PE Ratio: 48.19 PB Ratio: 15.88 GF Score: 74/100

DexCom Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 03:00PM GMT
David Ryan Lewis
Morgan Stanley, Research Division - MD

Welcome to the Morgan Stanley Healthcare conference 2020 here as we progress through the morning. My name is David Lewis, medical device analyst at Morgan Stanley. It's my pleasure to have with us here this morning, as we continue through the morning, DexCom and multiple members of management. We have a full house here. We have Quentin Blackford, the CFO and COO; Jereme Sylvain, SVP of Finance and Chief Accounting Officer; and Steve Pacelli, who just recently jumped in here last minute and is also going to help us out this morning.

So with that, I want to jump straight into questions. We're not going to do our traditional preamble here.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

Quentin, I wanted to start off very top line and we'll kind of jump into your core recovery in a bit. But look, we saw in the second quarter a 25% increase in sequential volumes in the business, despite kind of COVID-19. And I think we all know that TAM expanding drivers and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot